CLYM Stock Summary and Trading Ideas (Climb Bio | NASDAQ:CLYM)

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

What symbol and exchange does Climb Bio shares trade?

Climb Bio trades on the NASDAQ stock market under the symbol CLYM.

What is Climb Bio stock price doing today?

As of February 27, 2026, CLYM stock price declined to $7.15 with 552,660 million shares trading.

What is Climb Bio's Beta?

CLYM has a beta of 1.52, meaning it tends to be more sensitive to market movements. CLYM has a correlation of 0.06 to the broad based SPY ETF.

How much is Climb Bio worth?

CLYM has a market cap of $341.37 million. This is considered a Small Cap stock.

What are the top ETFs holding Climb Bio?

The top ETF exchange traded funds that CLYM belongs to (by Net Assets): VTI, VXF, IWC, DFAU, DFAC.

Is Climb Bio (CLYM) a good investment?

CLYM has outperformed the market in the last year with a price return of +414.4% while the SPY ETF gained +18.5%. CLYM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +288.6% and +26.1%, respectively, while the SPY returned +1.2% and +0.6%, respectively.

What are the support and resistance levels for Climb Bio (CLYM)?

CLYM support price is $6.86 and resistance is $7.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLYM shares will trade within this expected range on the day.